Vir Biotechnology不得不忙起来。7月,这家Biotech启动了第四款抗肿瘤候选药物的临床研究,尽管作为核心管线慢性丁型肝炎疗法tobevibart,相关III期试验也处于患者招募阶段。从数量上说,TCE大有成为Vir眼下故事的主角,公司官网对外披露的三款TCE都在加速跑步进场。最新进展来自VIR-5525,7月下旬已完成首位患者给药,Vir希望证明它用于非小细胞肺癌、结直肠癌、...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.